Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...

Celltrion's biosimilar Avtozma, used to treat inflammatory diseases, was approved for the U.S. market by the Food and Drug Administration.

Researchers have discovered a new type of tissue, a soft and flexible ‘fatty cartilage’ that could revolutionize the ...

Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday its new biosimilar for an autoimmune disease treatment has received approval from the U.S. Food and Drug Administration (FDA).

While you wait for the groundhog to make his determination this weekend, take some time to buff up your knowledge of rheumatoid arthritis, a chronic autoimmune disease that affects about 1.5 million ...

A genetic causal link between rheumatoid arthritis (RA) and an increased risk of traumatic and osteoporotic fractures ...

The technology was announced at the JP Morgan Healthcare Conference in San Francisco. In this project, the stakeholders aim to use a human reference genome to combine with patient data in order to try ...

We’ll discuss the distinct traits of psoriatic arthritis in Black patients, and the various environmental and genetic factors ...

Discover the reality behind Rheumatoid Arthritis, from its early onset potential to exercise benefits, backed by latest ...

The FDA has accepted Alvotech (ALVO) and Teva's (TEVA) applications for AVT05, their proposed biosimilar to J&J's ...